Triple negative breast cancer is a sub-type of the disease for which there are currently no targeted treatments. In addition, this form of breast cancer can be more aggressive than others. We need to understand what makes triple negative breast cancer different from other breast cancers so that drug targets can be identified that will lead to the development of effective targeted treatments for patients.
Triple negative breast cancer is an aggressive form of the disease which currently has no targeted treatments. Professor Tutt's project, jointly led by Dr Anita Grigoriadas at King’s College London, is using tumour samples donated from patients to identify genetic and molecular markers which are specific to triple negative disease. These markers will then be investigated in cell and animal models to aid the development of new targeted therapies for patients.
Part of the reason why there are no targeted treatments for triple negative breast cancer is because no one has yet discovered any molecular or genetic targets specific to this type of breast cancer. Professor Tutt is studying the biological characteristics of triple negative tumours to try and identify differences that set these cancers apart from other types. He then hopes to take these specific characteristics of triple negative breast cancer and use them to guide the development of targeted treatments.
What difference will this project make?
There are currently no targeted treatments available for patients with triple negative breast cancer. Professor Tutt and Dr Grigoriadas’s research in collaboration with Professor Tony Ng and Dr Sophia Karagiannis at the King’s College London Research Centre will lead to the development of new and effective drugs for triple negative breast cancer.
Make a donation to support our research
Help fund the future of research now to stop women dying from breast cancer.